Alumina's Deal With Grayle Puts You in Conflict With European Regulators

Facing off with the FTC isn't for the timid. But when your mission and your business model are aligned, the hard decisions – about risk, about investment, about priorities – become clearer. Francis deSouza is CEO of Illumina, the world’s dominant maker of gene sequencing technology. After playing a key role in the creation of Covid vaccines, Illumina is trying to acquire a company with a breakthrough cancer screening test, over the FTC's objections. DeSouza offers a personal reflection on the lessons and reality of grappling with regulators, highlighting levers that can help to accelerate scale. What underscores his entrepreneurial efforts is a passion for Illumina’s mission: improving human health by unlocking the power of the genome.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.